Illumina Inc. has filed a patent infringement lawsuit against Element Biosciences, alleging violations related to flow cell and imaging patents. Illumina stated that the decision to sue was based on careful consideration rather than the rival's market success. Element Biosciences responded by expressing pride in its history of innovation. Meanwhile, a coalition of universities and Nobel laureates secured a favorable appeals court ruling that grants them credit and lucrative rights to a breakthrough CRISPR gene-editing technology patent, resolving a dispute that has lasted over a decade. In parallel, researchers led by David Liu and Sam Sternberg have developed a powerful CRISPR-associated transposase system capable of efficiently inserting whole genes into precise locations within human DNA, representing an advancement over traditional CRISPR methods. The U.S. Patent and Trademark Office (USPTO) has also implemented a new interim workload management process, issuing discretionary denial decisions in several cases. Additionally, recent Federal Circuit rulings have provided clarity on patent eligibility and priority disputes, including the revival of a CRISPR-Cas9 patent priority dispute. These developments occur amid ongoing discussions about how new U.S. tariffs might impact patent litigation within the medical device industry.